Table 3. Transplant outcomes for all patients.

	All patients	By donor type
Measure	N=227	MRD (N=87)	MUD (N=108)	Haplo (N=32)
Day 30 chimerism
Donor engraftment
n	216,	87	98	31,
n (%)	210 (97)	86 (99)	94 (96)	30 (97)	0.441a
100% donor
n	208,	85,	93,	30,
n (%)	204 (98)	84 (99)	90 (97)	30 (100)	0.798a
CMV reactivation
n	224	87	106	31
n (%)	121 (54)	42 (48)	57 (54)	22 (71)	0.098a
EBV reactivation	0	0	0	0	-
CI aGVHD 2-4 (%) Day 100	30	31	29	29	0.709b
CI aGVHD 3-4 (%) Day 100	7	11	6	0	0.044b
CI cGVHD (Ext+Lim) (%) Year 3	34	43	30	19	0.094b
CI cGVHD (Ext) (%) Year 3	24	31	21	11	0.125b
Follow-up survivors Median (range), mo	31 (0.8–85.4)	45 (6.4-78.8)	40 (0.8-85.4)	13 (1.6-31.2)	<0.001c
CI Relapse (%)					0.750b
Day 100	8	7	8	10
		4	0	0
Year 1	26	28	23	33
CI Non-relapse mortality (%)					0.099b
Day 100	18	10	26	13
Year 1	27	20	35	24
Progression free survival (%)					0.120d
Day 100	74	83	65	78
Year 1	46	52	42	43
Year 3	31	36	27	30
Median (95% confidence interval) days	284 (215, 404)	411 (237, 757)	238 (160, 386)	276 (173, NE)
		10/10	10/10	5/10

a: acute; c: chronic; CI: cumulative incidence; CMV: cytomegalovirus; EBV: Epstein-Barr virus; CR: complete remission; ext: extensive; haplo: haploidentical donor; lim.: limited; Mel: melphalan; mo: month; MRD: matched related donor; MUD: matched unrelated donor;, n: number; NE = not estimable;

^a: Fisher's exact test.

^b: Gray's test.

^c: Kruskal-Wallis test.

^d: Log-rank test.